Population Studies and Precision Medicine
- Milestone 1.A •
Enable precision medicine research by supporting deep and longitudinal, molecular endophenotyping of existing and new, at-risk cohorts as well cohorts and/or individuals…
- Milestone 1.B •
Quantify the exposome in existing and new AD cohorts to gain a more precise measure of environmental exposure factors…
- Milestone 1.C •
Continue to establish new cohorts that include participants across diverse racial, ethnic and socioeconomic backgrounds…
- Milestone 1.D •
Develop state-of-the-art protocol for assessing dementia on large nationally representative samples…
- Milestone 1.E •
Expand existing large scale, open-science molecular profiling efforts
- Milestone 1.F •
Support the inclusion of measures of AD-related phenotypes and environmental exposures in non-AD cohorts...
- Milestone 1.G •
Augment current and future human cohorts with more advanced, longitudinal immunological profiling (e.g. Cytof) to enable precision medicine research...
- Milestone 1.H •
Enable access to electronic health records data and provide support for their integration with clinical and molecular data...
- Milestone 1.P •
Expand current efforts to address health disparities research questions relevant to AD/ADRD by leveraging new and existing exposome AD/ADRD studies, including the impact of institutional and policy
- Milestone 1.Q •
Support research that uses Artificial Intelligence (AI) and deep learning approaches for discovery and translational research.
- Milestone 1.R •
Support the research on the role of pollution and climate change on dementia risk.
AD Related Dementias - Specific
- Milestone 1.I •
Assess epidemiology and mechanistic pathways of disparities in health burden of AD/ADRD.
- Milestone 1.J •
Develop a system to monitor the magnitude and trends in health disparities in incidence of AD/ADRD.
- Milestone 1.K •
Characterize nervous system changes in LBD cohorts that have come to autopsy to identify disease-specific underlying mechanisms to guide biomarker and therapeutic approaches.
- Milestone 1.L •
Identify novel common and rare genetic variants, epigenetic changes, and environmental influences that impact the risk for and clinical features of LBD.
- Milestone 1.M •
Understand phenotypic heterogeneity and natural history in FTD.
- Milestone 1.N •
Encourage crosstalk and interdisciplinary collaboration between TBI and dementia researchers.
- Milestone 1.O •
Establish infrastructure to study TBI as a risk factor for AD/ADRD.